Open AccessEFFICACY OF GONADOTROPIN-RELEASING HORMONE AGONISTS TREATMENT OF THE SIMPLE ENDOMETRIAL HYPERPLASIA IN WOMEN OF REPRODUCTIVE AGE WITH OBESITY
Author(s) -
Н В Артымук,
Артымук Наталья Владимировна,
Yelena Aleksandrovna Shakirova,
Шакирова Елена Александровна
Publication year - 2013
Publication title -
žurnalʺ akušerstva i ženskihʺ boleznej
Language(s) - English
Resource type - Journals
eISSN - 1684-0461
pISSN - 1683-9366
DOI - 10.17816/jowd62116-21
Subject(s) - medicine , desogestrel , gonadotropin releasing hormone agonist , endometrial hyperplasia , ethinylestradiol , obesity , gonadotropin releasing hormone , estrogen , endocrinology , gynecology , hormone , hyperplasia , population , family planning , luteinizing hormone , environmental health , research methodology
A prospective, randomized, open, comparative study. There were 105 women of reproductive age with obesity and simple endometrial hyperplasia without atypia (EH) included into the study. 13 patients had left the study.31 patients took an agonist of gonadotropin-releasing hormone (aGnRH) Buserelin at the dose of 3.75 mg intramuscularly every 28 days. 33 patients took 10 mg of norethisteron per day. 28 patients took combined estrogen-gestagen drugs (30 mkg of ethinylestradiol + 150 mkg of desogestrel). The base therapy of obesity (a balanced diet and a physical activity)had been administered to all of the patients. Treatment in all groups lasted 6 months. The results of this study showed that usage of aGnRH in management of endometrial hyperplasia in patients of reproductive age with obesity is most effective and safe.